Health & Fitness
Health and FitnessHealth and Fitness 
Fri, February 3, 2012
Conditions of Growth, Economic Analysis -- Research Report on Pfizer Inc. and Boston Scientific Corporation
February 03, 2012 09:00 ET
Conditions of Growth, Economic Analysis -- Research Report on Pfizer Inc. and Boston Scientific Corporation
HONG KONG--(Marketwire - Feb 3, 2012) - Today, [ www.EquityLeader.com ] introduced research coverage of Pfizer Inc. (
Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experienced in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.
Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.
Equity Leader has decided to cover Pfizer Inc. for its current position within the healthcare industry. Pfizer Inc. is a research-based, global biopharmaceutical company. A copy of this report detailing Pfizer Inc. (
Equity Leader is also taking note of Boston Scientific Corporation for its changing role within the healthcare industry. Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. To download free research on Boston Scientific Corporation (
About Equity Leader
Whether you are a first time investor or seasoned market professional, Equity Leader provides the resources necessary to simplify your research process. Our focus has always been to empower investors with the information they need to make their own investment decisions.